Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Esophageal Neoplasms × eprenetapopt × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Myeloproliferative Disorders 2 Leukemia, Myelomonocytic, Chronic 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Esophageal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 20 Paclitaxel 13 Fluorouracil 13 Docetaxel 13 Radiotherapy 12 Oxaliplatin 11 Cisplatin 11 Capecitabine 8 Carboplatin 7 Leucovorin 6 Cetuximab 5 Nivolumab 4 Albumin-Bound Paclitaxel 4 atezolizumab 3 Trastuzumab 3 Ramucirumab 3 Irinotecan 3 Interleukin-2 3 Injections 3 Epirubicin 3 Drug Therapy 3 Dexamethasone 3 130-nm albumin-bound paclitaxel 3 tremelimumab 2 tisotumab vedotin 2 regorafenib 2 patritumab deruxtecan 2 oblimersen 2 nedaplatin 2 lenvatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡